26,831 Shares in Xencor, Inc. (NASDAQ:XNCR) Purchased by Sanctuary Advisors LLC

Sanctuary Advisors LLC bought a new stake in Xencor, Inc. (NASDAQ:XNCR) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 26,831 shares of the biopharmaceutical company’s stock, valued at approximately $540,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Louisiana State Employees Retirement System raised its position in shares of Xencor by 3.0% in the second quarter. Louisiana State Employees Retirement System now owns 31,000 shares of the biopharmaceutical company’s stock valued at $587,000 after buying an additional 900 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in Xencor by 3.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 500,708 shares of the biopharmaceutical company’s stock valued at $9,478,000 after acquiring an additional 15,974 shares during the last quarter. Panagora Asset Management Inc. lifted its stake in shares of Xencor by 9.4% during the 2nd quarter. Panagora Asset Management Inc. now owns 232,375 shares of the biopharmaceutical company’s stock worth $4,399,000 after purchasing an additional 20,043 shares during the period. Rhumbline Advisers boosted its holdings in shares of Xencor by 2.8% during the second quarter. Rhumbline Advisers now owns 154,573 shares of the biopharmaceutical company’s stock worth $2,926,000 after purchasing an additional 4,265 shares during the last quarter. Finally, TD Asset Management Inc grew its position in shares of Xencor by 1.5% in the second quarter. TD Asset Management Inc now owns 145,650 shares of the biopharmaceutical company’s stock valued at $2,757,000 after purchasing an additional 2,200 shares during the period.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Piper Sandler raised Xencor from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $20.00 to $30.00 in a research note on Monday, December 2nd. BMO Capital Markets restated an “outperform” rating and issued a $34.00 target price (up from $32.00) on shares of Xencor in a report on Friday, November 8th. Royal Bank of Canada increased their price target on shares of Xencor from $31.00 to $34.00 and gave the stock an “outperform” rating in a research note on Thursday, September 26th. Wedbush reissued an “outperform” rating and set a $38.00 price objective on shares of Xencor in a research note on Thursday, November 7th. Finally, Wells Fargo & Company assumed coverage on Xencor in a research report on Thursday, December 12th. They issued an “overweight” rating and a $37.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $36.56.

Xencor Trading Down 1.1 %

Shares of XNCR opened at $24.29 on Thursday. Xencor, Inc. has a 12 month low of $15.31 and a 12 month high of $27.24. The stock’s 50-day moving average is $23.59 and its two-hundred day moving average is $20.71. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. The stock has a market cap of $1.70 billion, a PE ratio of -7.59 and a beta of 0.69.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.98) by $0.27. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The firm had revenue of $10.70 million for the quarter, compared to analyst estimates of $14.59 million. During the same period in the previous year, the company posted ($0.40) EPS. Xencor’s revenue for the quarter was down 81.9% on a year-over-year basis. Equities analysts forecast that Xencor, Inc. will post -3.71 earnings per share for the current fiscal year.

Insider Activity at Xencor

In other news, VP John R. Desjarlais sold 68,684 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $23.48, for a total transaction of $1,612,700.32. Following the completion of the sale, the vice president now directly owns 200,104 shares in the company, valued at $4,698,441.92. This trade represents a 25.55 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Alan Bruce Montgomery sold 13,301 shares of Xencor stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $27.03, for a total value of $359,526.03. Following the sale, the director now directly owns 9,140 shares in the company, valued at approximately $247,054.20. The trade was a 59.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 136,050 shares of company stock valued at $3,277,609. Corporate insiders own 5.23% of the company’s stock.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.